Researchers demonstrate a new strategy to stop the TB bacterium

September 18, 2013, Brown University
Researchers demonstrate a new strategy to stop the TB bacterium
β-lactone 7, a small molecule that inhibits the ClpP enzyme in bacteria, may be important in development of new anti-bacterial drugs. The bacterium that causes tuberculosis cannot survive when ClpP is inhibited. Credit: Sello Lab / Brown University

To stay ahead in the race against drug-resistant infections, scientists constantly search for and exploit vulnerabilities in deadly bacteria. Now, researchers from Brown and the Massachusetts Institute of Technology have used a novel compound to exploit an Achilles' heel in the bacterium that causes tuberculosis.

In a series of , the researchers have shown that it is possible to kill Mycobacterium tuberculosis by inhibiting ClpP, a that is not targeted by any antibacterial drug on the market. The work is preliminary, but the researchers are hopeful it could point the way to to treat tuberculosis and other infections that are becoming resistant to traditional antibiotics.

"ClpP has emerged over the last decade or so as a potential drug target in bacteria because they require it to either live or to cause disease," said Jason Sello, associate professor of chemistry at Brown, who led the research. "Our findings indicate that chemical inhibition of the essential ClpP enzyme in Mycobacterium tuberculosis is a viable strategy in anti-tuberculosis drug development."

A paper describing the research has been accepted by the journal ACS Chemical Biology and published online.

The ClpP (pronounced "clip-P") enzyme is sometimes referred to as "the of the bacterial cell," Sello said. It degrades and eliminates proteins inside the cell that are misfolded, damaged, or have outlived their usefulness. While ClpP is dispensable in most bacteria, previous research has shown that it is absolutely essential for the viability of M. tuberculosis. When the gene that makes the protein is knocked out of the 's genome, the organism cannot survive.

"If you can inhibit the function of the enzyme with a small molecule, then you can kill the bacterium," Sello said. "When we began our work, the validity of this approach hadn't been demonstrated."

Sello and Corey Compton, a fourth-year graduate student in his group, set out to do so in the lab. Previous research had found that small molecules called ?-lactones inhibit the ClpP protein in other bacteria, suggesting that they might do the same in M. tuberculosis.

To find out, the researchers synthesized 14 ?-lactones, each with a slightly different chemical structure. They tested the effect of those molecules against Mycobacterium smegmatis, a close relative of the tuberculosis bacterium often used in the lab because it does not cause disease. Of the 14 molecules, four were shown to kill M. smegmatis in petri dish cultures. To see if the compounds could also kill M. smegmatis's deadly cousin, Sello and Compton sent them to the Institute for Tuberculosis Research at the University of Illinois for further testing. There, they found that the compounds were indeed effective in killing M. tuberculosis as well. The most potent compound they identified—?-lactone 7—had a structure that was different from all other known inhibitors of ClpP. The potency of this compound is in the same range as streptomycin, a clinically used tuberculosis drug.

The next step was to confirm that the ?-lactone 7 and the other compounds were killing the bacteria by reacting with and inhibiting ClpP, as the team expected. To do that, Sello and his team marked the ?-lactones with a kind of chemical handle that allowed them to retrieve any proteins with which the molecules had reacted. By putting these tagged ?-lactones in a culture of M. smegmatis (the tuberculosis stand-in), the researchers were able to show that they did in fact bind to the two proteins that construct the ClpP enzyme.

"These results were extremely gratifying," Compton said. "The compounds not only interacted with ClpP but they did so quite selectively."

The final step was proving that the reaction between the ?-lactones and ClpP actually resulted in the inhibition of the enzyme's activity. For that, Sello turned to Robert Sauer at MIT, an expert on the ClpP enzyme. Sauer and Karl Schmitz, a postdoctoral fellow in his research group, had developed an in vitro assay in which the activity of ClpP could be measured in a test tube. Using this assay, Schmitz and Sauer found that when ClpP was treated with ?-lactones the activity of the enzyme was inhibited.

Taken together, the results suggest that molecules that inhibit ClpP could be an important addition to the drug arsenal for fighting tuberculosis.

"Our data validate ClpP as a viable, antibacterial ," said Sello. "We have a high degree of confidence that inactivating ClpP will inhibit the growth of Mycobacterium tuberculosis. In principle, a pharmaceutical company could develop new drugs by using the structure of ?-lactone 7 as a starting point or by using ClpP inhibition as a design strategy".

Explore further: Potential new drug for tuberculosis

More information:

Related Stories

Potential new drug for tuberculosis

August 5, 2013

A new drug capable of inhibiting growth of Mycobacterium tuberculosis is reported this week in Nature Medicine. The findings may improve therapeutic options for the treatment of drug resistant tuberculosis (TB).

New compound defeats drug-resistant bacteria

November 28, 2011

It's no wonder that medicine's effort to combat bacterial infections is often described as an arms race. When new drugs are developed to combat infections, the bacterial target invariably comes up with a deterrent.

FDA approves first new tuberculosis in 40 years

December 31, 2012

The Food and Drug Administration says it has approved a Johnson & Johnson tuberculosis drug that is the first new medicine to fight the deadly infection in more than four decades.

Tuberculosis and Parkinson's disease linked by unique protein

September 4, 2013

A protein at the center of Parkinson's disease research now also has been found to play a key role in causing the destruction of bacteria that cause tuberculosis, according to scientists led by UC San Francisco microbiologist ...

Recommended for you

Asteroids, hydrogen make great recipe for life on Mars

March 26, 2019

A new study reveals asteroid impacts on ancient Mars could have produced key ingredients for life if the Martian atmosphere was rich in hydrogen. An early hydrogen-rich atmosphere on Mars could also explain how the planet ...

Cool Earth theory sheds more light on diamonds

March 26, 2019

A QUT geologist has published a new theory on the thermal evolution of Earth billions of years ago that explains why diamonds have formed as precious gemstones rather than just lumps of common graphite.

New cellulose-based material represents three sensors in one

March 26, 2019

Cellulose soaked in a carefully designed polymer mixture acts as a sensor to measure pressure, temperature and humidity at the same time. The measurements are completely independent of each other. The ability to measure pressure, ...

Physicists discover new class of pentaquarks

March 26, 2019

Tomasz Skwarnicki, professor of physics in the College of Arts and Sciences at Syracuse University, has uncovered new information about a class of particles called pentaquarks. His findings could lead to a new understanding ...

Study finds people who feed birds impact conservation

March 26, 2019

People in many parts of the world feed birds in their backyards, often due to a desire to help wildlife or to connect with nature. In the United States alone, over 57 million households in the feed backyard birds, spending ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

1 / 5 (7) Sep 19, 2013
And then it evolves again and comes back stronger, just like it has today.

Once a strong medication is found for TB, ruthless screening and vaccinations must begin, and immigration must STOP immediately, and have Australian-esque rules.

Europe pretty much wiped out TB, to have it come back with a vengeance due to stupid parents thinking vaccines are harmful, and lax immigration(I'm not against immigration, but test them for TB and vaccination must be compulsory for entry).

The best way to deal with any disease is prevention, not cure. If we find something to hit it on the head with, let's take that brief moment in time before it evolves a loohole and prevent it recurring

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.